{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Astrocytoma&page=2", "query": { "condition": "Malignant Astrocytoma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Astrocytoma&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-05-21T23:23:02.014Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03283631", "title": "Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Glioblastoma", "Recurrent Gliosarcoma" ], "interventions": [ { "name": "EGFRvIII-CARs", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Gary Archer Ph.D.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2018-05-30", "completion_date": "2020-06-30", "has_results": false, "last_update_posted_date": "2021-04-05", "last_synced_at": "2026-05-21T23:23:02.014Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03283631" }, { "nct_id": "NCT00499798", "title": "Changes in Semen or Sperm Caused by Temozolomide in Patients With Newly Diagnosed, Progressive, or Recurrent Primary Malignant Brain Tumors", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Brain and Central Nervous System Tumors", "Chemotherapeutic Agent Toxicity", "Infertility" ], "interventions": [], "intervention_types": [], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "MALE", "summary": "18 Years to 60 Years · Male only" }, "enrollment_count": 16, "start_date": "2004-08", "completion_date": "2014-09", "has_results": false, "last_update_posted_date": "2017-05-30", "last_synced_at": "2026-05-21T23:23:02.014Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00499798" }, { "nct_id": "NCT01017653", "title": "Panitumumab and Irinotecan for Malignant Gliomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Glioma of Brain" ], "interventions": [ { "name": "Irinotecan", "type": "DRUG" }, { "name": "Panitumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Annick Desjardins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2010-02", "completion_date": "2011-10", "has_results": true, "last_update_posted_date": "2013-09-04", "last_synced_at": "2026-05-21T23:23:02.014Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01017653" }, { "nct_id": "NCT00734864", "title": "Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma Multiforme", "Gliosarcoma", "Anaplastic Astrocytoma", "Anaplastic Oligodendroglioma", "Glioma" ], "interventions": [ { "name": "enzyme-inducing anti-epileptic drugs", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Annick Desjardins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2009-06", "completion_date": "2012-06", "has_results": false, "last_update_posted_date": "2012-11-21", "last_synced_at": "2026-05-21T23:23:02.014Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00734864" }, { "nct_id": "NCT00025675", "title": "Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "gefitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 105, "start_date": "2001-10-09", "completion_date": "2010-01-02", "has_results": false, "last_update_posted_date": "2018-06-26", "last_synced_at": "2026-05-21T23:23:02.014Z", "location_count": 12, "location_summary": "Los Angeles, California • San Francisco, California • Bethesda, Maryland + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00025675" }, { "nct_id": "NCT00002971", "title": "O(6)-Benzylguanine in Treating Patients With Malignant Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "O6-benzylguanine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": null, "start_date": "1997-06-19", "completion_date": "2009-01-01", "has_results": false, "last_update_posted_date": "2018-06-27", "last_synced_at": "2026-05-21T23:23:02.014Z", "location_count": 9, "location_summary": "Los Angeles, California • San Francisco, California • Boston, Massachusetts + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002971" }, { "nct_id": "NCT07285044", "title": "The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Amyloidosis", "Basal Cell Carcinoma", "Biliary Tract Carcinoma", "Bladder Carcinoma", "Breast Carcinoma", "Cervical Carcinoma", "Colorectal Carcinoma", "Endometrial Carcinoma", "Fallopian Tube Carcinoma", "Gastroesophageal Junction Carcinoma", "Glioblastoma", "Head and Neck Carcinoma", "Hematopoietic and Lymphatic System Neoplasm", "Hepatocellular Carcinoma", "Hodgkin Lymphoma", "Lung Carcinoma", "Malignant Solid Neoplasm", "Mantle Cell Lymphoma", "Melanoma", "Merkel Cell Carcinoma", "Multiple Myeloma", "Myelodysplastic Syndrome", "Ovarian Carcinoma", "Pancreatic Carcinoma", "Primary Peritoneal Carcinoma", "Prostate Carcinoma", "Renal Cell Carcinoma", "Squamous Cell Carcinoma", "Urothelial Carcinoma" ], "interventions": [ { "name": "Cancer Therapeutic Procedure", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2025-12-18", "completion_date": "2026-12-18", "has_results": false, "last_update_posted_date": "2026-05-18", "last_synced_at": "2026-05-21T23:23:02.014Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07285044" }, { "nct_id": "NCT05563272", "title": "89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cervical Cancer", "Colorectal Cancer", "Esophageal Cancer", "Gastric Cancer", "Glioblastoma Multiforme", "Cholangiocarcinoma", "Hepatocellular Carcinoma", "Head and Neck Squamous Cell Carcinoma", "Nasopharyngeal Carcinoma", "Non Small Cell Lung Cancer", "Small Cell Lung Cancer", "Epithelial Ovarian Cancer", "Pancreatic Ductal Adenocarcinoma", "Soft Tissue Sarcoma", "Gastric Adenocarcinoma", "Malignant Mesothelioma (MM)", "Von Hippel Lindau", "Bladder Cancer", "Bladder Urothelial Carcinoma" ], "interventions": [ { "name": "89Zr-girentuximab for PET/CT imaging of CAIX positive tumors", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Telix Pharmaceuticals (Innovations) Pty Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "95 Years", "sex": "ALL", "summary": "18 Years to 95 Years" }, "enrollment_count": 11, "start_date": "2023-06-06", "completion_date": "2025-05-09", "has_results": false, "last_update_posted_date": "2025-07-10", "last_synced_at": "2026-05-21T23:23:02.014Z", "location_count": 10, "location_summary": "Los Angeles, California • Miami, Florida • Boston, Massachusetts + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Traverse City", "state": "Michigan" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05563272" }, { "nct_id": "NCT00045721", "title": "Carmustine Implants and O(6)-Benzylguanine in Treating Children With Recurrent Malignant Glioma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "O6-benzylguanine", "type": "DRUG" }, { "name": "polifeprosan 20 with carmustine implant", "type": "DRUG" }, { "name": "adjuvant therapy", "type": "PROCEDURE" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "neoadjuvant therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Pediatric Brain Tumor Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "3 Years to 21 Years" }, "enrollment_count": 3, "start_date": "2003-03", "completion_date": "2004-07", "has_results": false, "last_update_posted_date": "2009-10-16", "last_synced_at": "2026-05-21T23:23:02.014Z", "location_count": 9, "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Boston, Massachusetts + 6 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00045721" }, { "nct_id": "NCT04222309", "title": "Laparoscopically Harvested Omental Free Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Recurrent Glioblastoma Multiforme (rGBM)", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioma", "Glioma, Malignant", "Glioblastoma", "Glioblastoma Multiforme", "Glioblastoma Multiforme of Brain", "GBM", "Brain Cancer" ], "interventions": [ { "name": "Laparoscopically harvested omental free flap", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Northwell Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2020-01-06", "completion_date": "2026-01-31", "has_results": false, "last_update_posted_date": "2025-04-09", "last_synced_at": "2026-05-21T23:23:02.014Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04222309" } ] }